Reported Earlier, "Ro, The Leading Direct-To-Patient Healthcare Company, Announced Today It Has Expanded Its Body Program Offering With The Launch Of Zepbound" - Yahoo Finance
Reported Earlier, "Ro, The Leading Direct-To-Patient Healthcare Company, Announced Today It Has Expanded Its Body Program Offering With The Launch Of Zepbound" - Yahoo Finance
Patients can explore the latest weight loss medications, understand their coverage and get comprehensive, high-quality care all in one platform
患者可以在一個平台上探索最新的減肥藥物，了解其承保範圍並獲得全面、高質量的護理
NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, announced today it has expanded its Body Program offering with the launch of Zepbound (tirzepatide) injection, the latest FDA-approved weight loss treatment from Eli Lilly and Company. Now, patients can come to Ro to access a broader range of weight loss treatment options based on their goals, insurance, budget, and a licensed provider's assessment. Each patient's Body Program journey is supported by personalized provider care, diagnostic testing, nurse coaching, and education.
紐約，2023 年 12 月 13 日 /PRNewswire/ — 領先的直接面向患者的醫療保健公司 Ro 今天宣佈，它已擴大其身體計劃產品範圍，推出了 Zepbound（替西帕肽）注射液，這是禮來公司批准的最新減肥療法。現在，患者可以根據自己的目標、保險、預算和持牌提供者的評估，前往 Ro 獲得更廣泛的減肥治療選擇。每位患者的身體計劃之旅都得到個性化提供者護理、診斷測試、護士指導和教育的支持。
In a 72-week clinical trial, Zepbound helped people without diabetes lose an average of 48 pounds, or about 20% of their body weight, when they paired the highest maintenance dose with diet and exercise changes (vs 3% with diet and exercise alone). Patients can work with their provider to determine if treatment is appropriate after completing an Online Visit and lab testing via Quest Diagnostics or Ro's at-home collection kit.
在一項爲期72周的臨床試驗中，Zepbound幫助沒有糖尿病的人將最高維持劑量與飲食和運動變化相結合，平均減掉48磅，約佔體重的20％（僅飲食和運動則爲3％）。患者通過 Quest Diagnostics 或 Ro 的家用採集套件完成在線就診和實驗室測試後，可以與醫務人員合作，確定治療是否合適。
"The possibilities of a world with Zepbound cannot be understated. Hopefully, with more options and more competition, we'll see expanded coverage of these innovative treatments and increased access for patients." said Zachariah Reitano, co-founder and CEO of Ro.
“Zepbound 世界的可能性不容低估。Ro聯合創始人兼首席執行官扎卡里亞·雷塔諾說，希望通過更多的選擇和更多的競爭，我們將看到這些創新療法的覆蓋範圍得到擴大，患者獲得更多的機會。
Launched in January 2023, Ro's Body Program has since grown to be the most comprehensive, high-quality weight loss offering available via telehealth, with additional medications and new tools to help patients reach their goals. This expansion includes:
Ro's Body Program 於 2023 年 1 月推出，現已發展成爲通過遠程醫療提供的最全面、最高質量的減肥服務，並提供其他藥物和新工具來幫助患者實現目標。此擴展包含：
Expanded GLP-1/GIP formulary to medication options that include Wegovy, Ozempic, Saxenda and now, Zepbound.
將 GLP-1/GIP 處方集擴展到包括 Wegovy、Ozempic、Saxenda 以及現在的 Zepbound 在內的藥物選項。
Integrated benefits verification to help patients understand their insurance coverage at the beginning and throughout their journey;
綜合福利驗證，幫助患者在開始和整個旅程中了解自己的保險範圍；
Automated side effect tracking to help patients communicate with their care team when additional support is needed. This data empowers Ro-affiliated providers to best support patients as they titrate medications;
自動跟蹤副作用，幫助患者在需要額外支持時與護理團隊進行溝通。這些數據使RO附屬提供商能夠在患者滴定藥物時爲他們提供最佳支持；
Integrated AI learning models to perform clerical tasks and give providers additional leverage to spend more time with patients and less on manual, administrative tasks;
集成人工智能學習模型來執行文書任務，爲提供者提供額外的槓桿作用，使他們能夠花更多的時間陪伴患者，減少在手動、管理任務上花費的時間；
Integrated with Apple Health to enable patients to share their weight loss data with their provider automatically; and more.
與 Apple Health 集成，使患者能夠自動與提供者共享減肥數據；等等。
"Zepbound is poised to be the most impactful anti-obesity medication we've seen so far in our lifetime. In the Body Program, we're pairing access to Zepbound and other effective medication options conveniently alongside everything a patient needs to start their treatment and at each step in their care journey," said Dr. Melynda Barnes, Chief Medical Officer of Ro. "Through Ro, patients can connect with a provider to evaluate all their options for GLP-1 treatment, understand their insurance coverage, and access ongoing, personalized provider care and coaching."
“Zepbound有望成爲我們一生中迄今爲止見過的最具影響力的抗肥胖藥物。在身體計劃中，我們將Zepbound和其他有效的藥物選擇與患者開始治療和護理過程中的每一步所需的一切便利配對。” Ro首席醫學官梅琳達·巴恩斯博士說。“通過 Ro，患者可以與提供者聯繫，評估他們對 GLP-1 治療的所有選擇，了解他們的保險覆蓋範圍，並獲得持續的個性化提供者護理和指導。”
To learn more about the Ro Body Program, click here. To see more safety information for Zepbound, including a Boxed Warning, click here or see below.
要了解有關 Ro Body Program 的更多信息，請單擊此處。要查看 Zepbound 的更多安全信息，包括盒裝警告，請點擊此處或查看下文。
譯文內容由第三人軟體翻譯。